Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):276-278. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0220

View: 1515 Download: 24

Review

Comprehensive approach to controlling chronic hepatitis B in China

Shan Shan, Xinyan Zhao, Jidong Jia

Clin Mol Hepatol. 2024;30(2):135-143. Published online January 5, 2024

DOI: https://doi.org/10.3350/cmh.2023.0412

View: 2621 Download: 176

Original Article

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation

Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng, Tzu-Haw Chen, Yi-Ling Wu, Chieh-Chang Chen, Yu-Jen Fang, Tzeng-Huey Yang, Mindie H. Nguyen, Jaw-Town Lin, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(1):98-108. Published online December 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0194

View: 2095 Download: 145 Web of Science: 1 Crossref: 6

Review

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3345 Download: 197 Web of Science: 8 Crossref: 11

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 3652 Download: 105

Original Article

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis

Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim

Clin Mol Hepatol. 2023;29(4):1013-1028. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0131

View: 3368 Download: 138 Web of Science: 2 Crossref: 3

Snapshot

HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?

Soon Kyu Lee, Jung Hyun Kwon

Clin Mol Hepatol. 2023;29(3):825-827. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0185

View: 2592 Download: 97

Original Article

Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients

Xiaoning Wu, Xiaoqian Xu, Jialing Zhou, Yameng Sun, Huiguo Ding, Wen Xie, Guofeng Chen, Anlin Ma, HongXin Piao, Bingqiong Wang, Shuyan Chen, Tongtong Meng, Xiaojuan Ou, Hwai-I Yang, Jidong Jia, Yuanyuan Kong, Hong You

Clin Mol Hepatol. 2023;29(3):747-762. Published online May 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0121

View: 2587 Download: 135 Crossref: 1

Review

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391

View: 4029 Download: 330 Web of Science: 10 Crossref: 8

Guideline

KASL clinical practice guidelines for management of autoimmune hepatitis 2022

Clin Mol Hepatol. 2023;29(3):542-592. Published online May 3, 2023

DOI: https://doi.org/10.3350/cmh.2023.0087

View: 3623 Download: 298 Web of Science: 2 Crossref: 4

Editorial

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 2743 Download: 86 Web of Science: 1 Crossref: 1

The clinical management of hepatocellular carcinoma in China: Progress and challenges

Shan Shan, Jidong Jia

Clin Mol Hepatol. 2023;29(2):339-341. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0077

View: 3054 Download: 99 Web of Science: 2 Crossref: 2

What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?

Min Kyung Park, Yoon Jun Kim

Clin Mol Hepatol. 2023;29(2):332-334. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0080

View: 2486 Download: 49

Review

The role of different viral biomarkers on the management of chronic hepatitis B

Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):263-276. Published online January 19, 2023

DOI: https://doi.org/10.3350/cmh.2022.0448

View: 5008 Download: 304 Web of Science: 8 Crossref: 10

Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao

Clin Mol Hepatol. 2023;29(2):206-216. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0402

View: 6071 Download: 437 Web of Science: 26 Crossref: 25

Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective

Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi

Clin Mol Hepatol. 2023;29(2):197-205. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0404

View: 4421 Download: 226 Web of Science: 11 Crossref: 10

Correspondence

Correspondence on Editorial regarding “HBV pgRNA and HBcrAg reductions at week 4 predict favourable HBsAg response upon long-term nucleos(t)ide analogue in CHB”

Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):191-193. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0410

View: 2738 Download: 64

Original Article

Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

Lung-Yi Mak, Danny Wong, Alison Kuchta, Martina Hilfiker, Aaron Hamilton, Ning Chow, XianHua Mao, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(1):146-162. Published online August 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0172

View: 5660 Download: 225 Web of Science: 10 Crossref: 10

Review

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0186

View: 7477 Download: 366 Web of Science: 12 Crossref: 13

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0084 Correction in: Clin Mol Hepatol 2022;28(4):940

View: 10845 Download: 594 Web of Science: 39 Crossref: 48

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Woo Lee, Yong Kyun Cho

Clin Mol Hepatol. 2021;27(3):363-401. Published online June 22, 2021

DOI: https://doi.org/10.3350/cmh.2021.0178

View: 18030 Download: 1,223 Web of Science: 144 Crossref: 158

Review

Recent updates on the management of autoimmune hepatitis

Atsumasa Komori

Clin Mol Hepatol. 2021;27(1):58-69. Published online December 10, 2020

DOI: https://doi.org/10.3350/cmh.2020.0189

View: 15090 Download: 1,168 Web of Science: 63 Crossref: 74

Original Article

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients

Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik

Clin Mol Hepatol. 2020;26(4):516-528. Published online September 11, 2020

DOI: https://doi.org/10.3350/cmh.2020.0016

View: 6414 Download: 210 Web of Science: 45 Crossref: 41

Review

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kyung-Soo Kim, Byung-Wan Lee

Clin Mol Hepatol. 2020;26(4):430-443. Published online August 14, 2020

DOI: https://doi.org/10.3350/cmh.2020.0137

View: 9998 Download: 479 Web of Science: 37 Crossref: 38

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 14576 Download: 390 Web of Science: 38 Crossref: 42

Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Tommaso Lorenzo Parigi, Maria Corina Plaz Torres, Alessio Aghemo

Clin Mol Hepatol. 2019;25(4):360-365. Published online May 2, 2019

DOI: https://doi.org/10.3350/cmh.2019.0022

View: 5650 Download: 243 Web of Science: 9 Crossref: 10

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2019;25(2):93-159. Published online June 12, 2019

DOI: https://doi.org/10.3350/cmh.2019.1002

View: 24851 Download: 649 Web of Science: 166 Crossref: 149

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

Clin Mol Hepatol. 2018;24(3):169-229. Published online August 10, 2018

DOI: https://doi.org/10.3350/cmh.2018.1004

View: 14487 Download: 221 Web of Science: 19 Crossref: 27

Original Article

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion

Jihyun An, Kwang Sun Lee, Kang Mo Kim, Do Hyun Park, Sang Soo Lee, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee

Clin Mol Hepatol. 2017;23(2):160-169. Published online May 16, 2017

DOI: https://doi.org/10.3350/cmh.2016.0088

View: 8970 Download: 240 Web of Science: 31 Crossref: 27

Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization

Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi

Clin Mol Hepatol. 2016;22(4):458-465. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0054

View: 8969 Download: 134 Web of Science: 10 Crossref: 10

1 | 2 | 3 |

Viewed By 5351	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4958	MAFLD: How is it different from NAFLD?
Viewed By 4656	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4332	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3913	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 169	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 108	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 80	MAFLD: How is it different from NAFLD?
Cited By 77	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search